Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
Novartis Snags Exclusive Rights from Mesoblast for MSC Therapy Against COVID-Induced ARDS
-
Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other indications
-
Addition of remestemcel-L could expand Novartis respiratory portfolio by adding potential first-in-class ARDS therapy using innovative cell-based technology with platform potential
-
Deal includes $50 million upfront cash payment and equity/share subscription, plus performance-based milestones and royalties for access to a cell-therapy based platform with worldwide rights to a range of potential indications
Basel, November 19, 2020 — Novartis announced that it entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19. ARDS is an area of significant unmet need, with an approximate 40% mortality rate with current standard of care, which includes prolonged ICU treatment and mechanical ventilation.1,2
As the potential first ARDS therapy, remestemcel-L will use mesenchymal stromal cells (MSCs), a cell-based platform technology, to treat this deadly condition and improve outcomes. Remestemcel-L is currently being studied in COVID-19-related ARDS in an ongoing 300-patient Phase III study.3 Novartis intends to initiate a Phase III study in non-COVID-19-related ARDS after the anticipated closing of the license agreement and successful completion and outcome of the current study. [Read more…]
Invitrx Therapeutics to Co-Sponsor Baylx, Inc’s US FDA Approved Umbilical Cord Tissue Mesenchymal Stem Cells Product for COVID-19
Irvine, CA., November, 23 2020 — Invitrx Therapeutics has formally signed a joint venture agreement with Baylx, Inc. (Baylx), to co-sponsor Baylx’s FDA approved Investigational New Drug (IND) application for BX-U001, a fresh, non-frozen human umbilical cord tissue mesenchymal stem cells (hUC-MSC) product in patients with COVID-19. [Read more…]
Organicell Announces Additional Site for Phase I/II Clinical Trial of Zofin™ for Treatment of COVID-19
Miami, FL (November 18, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it is now enrolling patients at an additional site, Larkin Hospital North located in Hialeah, Florida for its Phase I/II clinical trial for the use of its Zofin™ therapeutic in treatment of COVID-19. [Read more…]
Proteintech and HebeCell to Collaborate on Nanobody iPSC-derived NK Cells
CHICAGO & NATICK, Massachusetts, Nov 11, 2020–Proteintech and HebeCell announce their collaborative partnership to develop proprietary nanobody based chimeric antigen receptor (nCAR) technology for the development and commercialization of iPSC-derived natural killer (iPSC-nCAR-NK) cells, a promising cellular immunotherapy treatment for cancer and other diseases. [Read more…]
- « Previous Page
- 1
- …
- 62
- 63
- 64
- 65
- 66
- …
- 122
- Next Page »